FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) Fundamental Analysis & Valuation

NASDAQ:FBIOP • US34960Q2084

Current stock price

13.78 USD
-0.11 (-0.79%)
Last:

This FBIOP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. FBIOP Profitability Analysis

1.1 Basic Checks

  • FBIOP had negative earnings in the past year.
  • In the past year FBIOP has reported a negative cash flow from operations.
  • In the past 5 years FBIOP always reported negative net income.
  • In the past 5 years FBIOP always reported negative operating cash flow.
FBIOP Yearly Net Income VS EBIT VS OCF VS FCFFBIOP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

  • FBIOP's Return On Assets of -2.94% is amongst the best of the industry. FBIOP outperforms 86.07% of its industry peers.
  • FBIOP's Return On Equity of -9.55% is amongst the best of the industry. FBIOP outperforms 86.27% of its industry peers.
Industry RankSector Rank
ROA -2.94%
ROE -9.55%
ROIC N/A
ROA(3y)-36.39%
ROA(5y)-27.89%
ROE(3y)-252.68%
ROE(5y)-172.79%
ROIC(3y)N/A
ROIC(5y)N/A
FBIOP Yearly ROA, ROE, ROICFBIOP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

1.3 Margins

  • Looking at the Gross Margin, with a value of 71.56%, FBIOP belongs to the top of the industry, outperforming 81.04% of the companies in the same industry.
  • FBIOP's Gross Margin has declined in the last couple of years.
  • FBIOP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 71.56%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.13%
GM growth 5Y-2.19%
FBIOP Yearly Profit, Operating, Gross MarginsFBIOP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. FBIOP Health Analysis

2.1 Basic Checks

  • FBIOP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • FBIOP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
FBIOP Yearly Shares OutstandingFBIOP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
FBIOP Yearly Total Debt VS Total AssetsFBIOP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -4.44, we must say that FBIOP is in the distress zone and has some risk of bankruptcy.
  • FBIOP has a worse Altman-Z score (-4.44) than 61.12% of its industry peers.
  • FBIOP has a Debt/Equity ratio of 0.86. This is a neutral value indicating FBIOP is somewhat dependend on debt financing.
  • FBIOP has a Debt to Equity ratio of 0.86. This is in the lower half of the industry: FBIOP underperforms 73.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF N/A
Altman-Z -4.44
ROIC/WACCN/A
WACC9.65%
FBIOP Yearly LT Debt VS Equity VS FCFFBIOP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M -150M

2.3 Liquidity

  • FBIOP has a Current Ratio of 2.19. This indicates that FBIOP is financially healthy and has no problem in meeting its short term obligations.
  • FBIOP has a Current ratio of 2.19. This is in the lower half of the industry: FBIOP underperforms 75.24% of its industry peers.
  • A Quick Ratio of 1.97 indicates that FBIOP should not have too much problems paying its short term obligations.
  • FBIOP has a Quick ratio of 1.97. This is in the lower half of the industry: FBIOP underperforms 76.40% of its industry peers.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 1.97
FBIOP Yearly Current Assets VS Current LiabilitesFBIOP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. FBIOP Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 73.09% over the past year.
EPS 1Y (TTM)73.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%6.34%

3.2 Future

  • FBIOP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 93.66% yearly.
  • The Revenue is expected to grow by 57.99% on average over the next years. This is a very strong growth
EPS Next Y101.16%
EPS Next 2Y93.66%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year49.34%
Revenue Next 2Y40.76%
Revenue Next 3Y108.71%
Revenue Next 5Y57.99%

3.3 Evolution

FBIOP Yearly Revenue VS EstimatesFBIOP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
FBIOP Yearly EPS VS EstimatesFBIOP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

2

4. FBIOP Valuation Analysis

4.1 Price/Earnings Ratio

  • FBIOP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Based on the Price/Forward Earnings ratio of 1350.98, the valuation of FBIOP can be described as expensive.
  • Based on the Price/Forward Earnings ratio, FBIOP is valued cheaper than 87.43% of the companies in the same industry.
  • FBIOP is valuated expensively when we compare the Price/Forward Earnings ratio to 23.68, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 1350.98
FBIOP Price Earnings VS Forward Price EarningsFBIOP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 200 400 600 800 1K

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FBIOP Per share dataFBIOP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • FBIOP's earnings are expected to grow with 93.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y93.66%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. FBIOP Dividend Analysis

5.1 Amount

  • No dividends for FBIOP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

FBIOP Fundamentals: All Metrics, Ratios and Statistics

FORTRESS BIOTECH INC - FBIO 9 3/8 PERP

NASDAQ:FBIOP (4/9/2026, 8:26:08 PM)

13.78

-0.11 (-0.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-31
Earnings (Next)05-13
Inst Owners18.92%
Inst Owner ChangeN/A
Ins Owners14.74%
Ins Owner ChangeN/A
Market Cap443.72M
Revenue(TTM)N/A
Net Income(TTM)-5.34M
Analysts82.5
Price Target65.41 (374.67%)
Short Float %0%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.22
Dividend Growth(5Y)-17.74%
DP-12.44%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)44.76%
Min EPS beat(2)-36.17%
Max EPS beat(2)125.68%
EPS beat(4)3
Avg EPS beat(4)24.21%
Min EPS beat(4)-36.17%
Max EPS beat(4)125.68%
EPS beat(8)6
Avg EPS beat(8)23.87%
EPS beat(12)7
Avg EPS beat(12)18.85%
EPS beat(16)9
Avg EPS beat(16)-3.2%
Revenue beat(2)1
Avg Revenue beat(2)-3.53%
Min Revenue beat(2)-17.76%
Max Revenue beat(2)10.71%
Revenue beat(4)2
Avg Revenue beat(4)-1.31%
Min Revenue beat(4)-17.76%
Max Revenue beat(4)10.85%
Revenue beat(8)3
Avg Revenue beat(8)-5.02%
Revenue beat(12)5
Avg Revenue beat(12)3.82%
Revenue beat(16)6
Avg Revenue beat(16)-2.87%
PT rev (1m)0%
PT rev (3m)50.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)131.88%
EPS NY rev (1m)0%
EPS NY rev (3m)150%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)13.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1350.98
P/S 7.12
P/FCF N/A
P/OCF N/A
P/B 7.94
P/tB 16.32
EV/EBITDA N/A
EPS(TTM)-0.88
EYN/A
EPS(NY)0.01
Fwd EY0.07%
FCF(TTM)-2.52
FCFYN/A
OCF(TTM)-2.05
OCFYN/A
SpS1.93
BVpS1.73
TBVpS0.84
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.94%
ROE -9.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 71.56%
FCFM N/A
ROA(3y)-36.39%
ROA(5y)-27.89%
ROE(3y)-252.68%
ROE(5y)-172.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.13%
GM growth 5Y-2.19%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.19
Quick Ratio 1.97
Altman-Z -4.44
F-Score4
WACC9.65%
ROIC/WACCN/A
Cap/Depr(3y)152.42%
Cap/Depr(5y)127.86%
Cap/Sales(3y)11.86%
Cap/Sales(5y)9.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.67%
EPS Next Y101.16%
EPS Next 2Y93.66%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%6.34%
Revenue Next Year49.34%
Revenue Next 2Y40.76%
Revenue Next 3Y108.71%
Revenue Next 5Y57.99%
EBIT growth 1Y10.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.86%
EBIT Next 3Y23.67%
EBIT Next 5YN/A
FCF growth 1Y42.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y53.14%
OCF growth 3YN/A
OCF growth 5YN/A

FORTRESS BIOTECH INC - FBIO 9 3/8 PERP / FBIOP Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for FORTRESS BIOTECH INC - FBIO 9 3/8 PERP?

ChartMill assigns a fundamental rating of 2 / 10 to FBIOP.


What is the valuation status for FBIOP stock?

ChartMill assigns a valuation rating of 2 / 10 to FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP). This can be considered as Overvalued.


How profitable is FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) stock?

FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) has a profitability rating of 2 / 10.


How sustainable is the dividend of FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) stock?

The dividend rating of FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) is 0 / 10 and the dividend payout ratio is -12.44%.